MRI Interventions, Inc. — 2012 Form 10-K Summary
Reporting period and business: Fiscal year ended December 31, 2012. The supplied filing is for MRI Interventions, Inc., not Clearpoint Neuro, Inc.; confirm the issuer identity before relying on this summary. The company develops MRI-guided minimally invasive medical-device platforms. ClearPoint, for neurological procedures, was commercially available in the U.S. and EU; ClearTrace, for cardiac procedures, remained in preclinical development without regulatory clearance. At year-end, 20 ClearPoint systems were installed: 18 in the U.S. and two in Europe.
Financial results and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $5.06 million | $3.82 million |
| Product revenue | $1.17 million | $1.15 million |
| Operating loss | $3.13 million | $5.92 million |
| Net loss | $5.71 million | $8.31 million |
| Net loss per share | $0.14 | $0.52 |
| Cash used in operations | $7.43 million | $6.24 million |
- Revenue rose 32%. The increase primarily reflected $3.35 million of related-party license revenue, up from $2.60 million, and service revenue of $541,000. Product revenue was broadly flat. Disposable products made up 87% of product sales, versus 39% in 2011; management said disposable margins are typically higher than reusable-system margins. The filing does not provide a clear overall gross-margin percentage.
- Research and development expense fell 42% to $2.48 million as ClearTrace spending was reduced while the company sought funding and prioritized ClearPoint commercialization. Selling, general and administrative expense rose 25% to $6.03 million, including higher share-based compensation and public-company costs.
- Net loss improved in part because of an $883,000 reversal of previously accrued incentive-program R&D costs. Interest expense was $2.59 million and included a substantial non-cash write-off of debt discounts and financing costs related to 2012 note conversions.
- At year-end, cash and cash equivalents were $1.62 million, current assets $3.08 million, current liabilities $4.18 million, total assets $5.55 million, and total liabilities $11.29 million. Stockholders’ deficit was $5.74 million. Long-term liabilities included $4.34 million of related-party convertible notes, $2.00 million of convertible notes, and junior secured notes with a $196,000 net carrying value; the junior notes’ stated principal was $3.00 million, substantially offset by an unamortized discount.
- Cash from financing was $9.04 million in 2012, principally from the February unit offering and July private placement. Cash increased by $1.47 million during the year.
Changes, outlook, and key risks
- During February 2012, convertible notes and accrued interest totaling approximately $11.79 million converted into common shares, and 7.965 million preferred shares also converted. This materially reduced reported liabilities but increased shares outstanding.
- Management expected continued losses through at least 2013 and planned to increase ClearPoint sales and marketing spending. It stated that year-end cash plus net proceeds of approximately $9.9 million from a January 2013 private offering were expected to fund anticipated requirements through at least March 2014. Additional financing might be needed; equity or convertible financing could dilute shareholders.
- ClearTrace development had no stated completion or regulatory-submission timetable. Management identified development, clinical, regulatory and commercialization uncertainty, as well as competition from larger companies, as material risks.
- Other significant risks include uncertain physician and hospital adoption, reimbursement, reliance on single-source suppliers and limited manufacturing capacity, customer concentration, intellectual-property dependence, and the company’s ability to raise capital. The company disclosed a $3.5 million Boston Scientific loan arrangement with covenants that could require assignment of certain patent rights if specified financial or other requirements were not met.
- The January 2013 financing included common shares and warrants and had registration-related potential damages of up to approximately $1.3 million. Subsequent to year-end, a strategic partner revoked its election to convert a 2011 note; a March 2013 amendment removed its conversion feature, changed its interest rate and principal, and retained an April 2016 maturity. These are subsequent events, not 2012 operating results.
- No material pending legal proceedings were reported. Management judged disclosure controls effective at year-end; the filing did not include an audit of internal control over financial reporting.
Investor facts to verify
- Confirm the filing issuer and its relationship, if any, to Clearpoint Neuro, Inc.; this 10-K names MRI Interventions, Inc.
- Review the audited statements and notes for the composition, priority, maturity, and covenants of debt, including the later note amendments and the patent-assignment provisions.
- Check whether ClearPoint installations and procedure volumes are translating into recurring disposable-product revenue and improved product economics.
- Assess the reliance on related-party license revenue and the status and potential value of Boston Scientific and Siemens arrangements.
- Verify post-year-end cash, financing costs, warrant dilution, registration obligations, and the assumptions supporting management’s March 2014 liquidity estimate.
- Track ClearTrace development progress, clinical evidence, and regulatory requirements, particularly the anticipated PMA pathway for its cardiac ablation catheter in the U.S.